Search research articles
Contact Us
Filters
Showing results (81-90 of 121) with videos related to
Page
of 13
Sort By:
The Journal of Biological Chemistry
|
January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694
Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
American Journal of Hematology
|
February 3, 2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
Kami Maddocks, Lai Wei, Darlene Rozewski, et al.
Blood
|
May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Blood
|
October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
Ta-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
Plos One
|
July 20, 2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, et al.
Blood
|
September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Leukemia Research
|
July 31, 2007
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
Rebekah L Browning, Susan M Geyer, Amy J Johnson, et al.
Blood
|
December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Leukemia Research
|
March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
Mark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 121) with videos related to
Sort By:
Page
of 13
The Journal of Biological Chemistry
|
January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694
Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
American Journal of Hematology
|
February 3, 2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
Kami Maddocks, Lai Wei, Darlene Rozewski, et al.
Blood
|
May 15, 2015
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu, Jennifer A Woyach, Yiming Zhong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Blood
|
October 9, 2014
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
Ta-Ming Liu, Yonghua Ling, Jennifer A Woyach, et al.
Plos One
|
July 20, 2016
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, et al.
Blood
|
September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Leukemia Research
|
July 31, 2007
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
Rebekah L Browning, Susan M Geyer, Amy J Johnson, et al.
Blood
|
December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Leukemia Research
|
March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
Mark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Page
of 13